PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Penzak SR. Am J Cardiovasc Drugs. Jan 2002; 2(2): 91-106 Pubmed [6901]
Penzak SR. J Acquir Immune Defic Syndr. Dec 2005; 40(5): 573-80 Pubmed [6476]
Penzak SR. Ther Drug Monit. Jun 2004; 26(3): 322-30 Pubmed [6416]
Penzner JB. J Child Adolesc Psychopharmacol. Oct 2009; 19(5): 563-73 Pubmed, Volltext, DOI [3280]
Perazella MA. Am J Med Sci. Jun 2003; 325(6): 349-62 Pubmed [5695]
Perdix (Moexipril), Schwarz Pharma Ltd. Summary of product characteristics, March 2000 [1734]
Pereira BB. J Toxicol Environ Health B Crit Rev. Apr 2020; : 1-5 Pubmed [8904]
Pereira MA. Rev Bras Anestesiol. Jan 1972; 22(1): 10-9 Pubmed [10000]
Peremans K. Nucl Med Commun. Aug 2008; 29(8): 724-9 Pubmed [4789]
Perez Jimenez TE. Drug Metab Dispos. Oct 2016 Pubmed, Volltext, DOI [4332]
Perez Ruixo JJ. J Clin Pharmacol. Mar 2015; 55 Suppl 3: S85-92 Pubmed [4017]
Perez-Lloret S. CNS Drugs. Aug 2016; 30(8): 703-17 Pubmed [10439]
Pérez-Torre P. Neurologia (Engl Ed). Sep 2021 Pubmed [12181]
Pergolizzi J. Pain Pract. Jul 2008; 8(4): 287-313 Pubmed [8991]
Pericàs JM. Clin Microbiol Infect. Jun 2018; 24(6): 673-676 Pubmed [8121]
Periclou A. Eur J Drug Metab Pharmacokinet. Jan 2021; 46(1): 53-69 Pubmed [11179]
Periclou A. J Clin Pharmacol. Apr 2010; 50(4): 422-33 Pubmed [3556]
Peritogiannis et al. (2007) J Clin Psychopharmacol 27(2):235-238 [2964]
Peritogiannis et al. Schizophr Res. 2005 Nov 15;79(2-3):345-6 [1471]
Peritogiannis V. Gen Hosp Psychiatry. May 2007; 29(3): 281-2 Pubmed [6237]
Peritogiannis V. Schizophr Res. Nov 2005; 79(2-3): 345-6 Pubmed [8963]
Perković Vukčević N. Pharmaceuticals (Basel). Feb 2024; 17(2) Pubmed [13814]
Perlemuter G. CNS Drugs. Sep 2016; 30(9): 877-88 Pubmed [4990]
Perlman BB. Lancet. Feb 1990; 335(8686): 416 Pubmed [1721]
Perloff ES. Drug Metab Dispos. Jun 2005; 33(6): 764-70 Pubmed [6301]
Perloff MD. J Pharm Sci. Nov 2001; 90(11): 1829-37 Pubmed [7974]
Perloff MD. Xenobiotica. Feb 2004; 34(2): 133-50 Pubmed [9705]
Perry CM. Drugs. Jul 1997; 54(1): 81-7; discussion 88 Pubmed [11950]
Perry LA. Cochrane Database Syst Rev. May 2018; 5: CD011943 Pubmed, Volltext, DOI [9871]
Perry ME. Int J STD AIDS. Aug 2013; 24(8): 639-42 Pubmed [7041]
Perry NK. Postgrad Med J. Apr 2000; 76(894): 254-6 Pubmed, Volltext, DOI [3270]
Perry PJ. J Clin Psychopharmacol. Feb 1993; 13(1): 46-51 Pubmed [1552]
Perse TL. Am J Psychiatry. Dec 1987; 144(12): 1543-8 Pubmed [12920]
Person, Siwers. Swed Dent J (1975) 68, 9-18 [1946]
Persson CG. Life Sci. Mar 1986; 38(12): 1057-72 Pubmed [6938]
Persson MP. Clin Pharmacol Ther. Mar 1988; 43(3): 324-31 Pubmed [1852]
Pertz HH. Planta Med. Jul 2011; 77(10): 973-8 Pubmed [12324]
Perucca Br J Clin Pharmacol 2005; 61:246-255 [2063]
Perucca E. Br J Clin Pharmacol. Aug 1977; 4(4): 485-6 Pubmed, Volltext [1596]
Perucca E. Br J Clin Pharmacol. Mar 2006; 61(3): 246-55 Pubmed, Volltext, DOI [427]
Perucca E. Clin Pharmacokinet. Jan 1982; 7(1): 57-84 Pubmed [9296]
Perucca E. Clin Pharmacokinet. Jul 1996; 31(1): 29-46 Pubmed [9350]
Perucca E. Clin Pharmacol Ther. Nov 1994; 56(5): 471-6 Pubmed [1473]
Perucca E. Epilepsia. Jan 1999; 40 Suppl 9: S7-13 Pubmed [9416]
Perucca E. Epilepsia. Jul 2008; 49(7): 1123-41 Pubmed [470]
Perucca E. Epilepsy Res. Feb 2003; 53(1-2): 47-56 Pubmed [9331]
Perucca Emilio, Johannessen Svein I, Treatment of Epilepsy: Focus on Levetiracetam. The ideal pharmacokinetic properties of an antiepileptic drug: how close does Ievetiracetam come? Epileptic Disord 2003; 5 (Supp/ 7): S17-S26 [2562]
Perugi G. Pharmacopsychiatry. Jul 2001; 34(4): 137-41 Pubmed [10387]
Pesavento TE. J Am Soc Nephrol. Jun 1996; 7(6): 831-5 Pubmed [4272]
Pescovitz MD. Am J Transplant. Oct 2009; 9(10): 2324-30 Pubmed [12742]
Pessanha TM. AIDS. Feb 2007; 21(4): 529-32 Pubmed [6388]
Peter JV. Med J Aust. Aug 2006; 185(4): 223-5 Pubmed [6513]
Peter Overbeck. Duale RAS-Blockade Nutzen plus Nutzen ergibt keinen Nutzen. ÄrzteZeitung. Stand Oct 2019. https://www.aerztezeitung.de/medizin/krankheiten/herzkreislauf/herzinsuffizienz/article/834825/duale-ras-blockade-nutzen-plus-nutzen-ergibt-keinen-nutzen.html [8091]
Peters DH. Drugs. May 1993; 45(5): 760-87 Pubmed [9415]
Peters O. J Nutr Health Aging. Jan 2012; 16(6): 544-8 Pubmed [9944]
Peters U. Dtsch Med Wochenschr. Nov 1974; 99(47): 2381-6 Pubmed [6193]
Petersen KU. Curr Drug Metab. Aug 2024 Pubmed [13784]
Petersen P. Acta Med Scand. Jan 1985; 217(4): 423-7 Pubmed [5579]
Peterson D. Am J Health Syst Pharm. Jun 2017; 74(12): 888-892 Pubmed [6583]
Peterson TC. Biochem Pharmacol. Jul 2004; 68(2): 395-402 Pubmed [3310]
Petit E. Case Rep Emerg Med. Dec 2018; 2018: 4107450 Pubmed, Volltext, DOI [7169]
Petitcollin A. J Antimicrob Chemother. Dec 2016; 71(12): 3482-3486 Pubmed [7468]
Petitpierre B. Int J Clin Pharmacol. Jun 1972; 6(2): 120-4 Pubmed [1785]
Petri N. Int J Clin Pharmacol Ther. Feb 2006; 44(2): 71-9 Pubmed [8344]
Petrò E. Neuropsychiatr Dis Treat. Mar 2016; 12: 559-69 Pubmed, Volltext, DOI [10157]
Pettit NN. J Antimicrob Chemother. Aug 2017; 72(8): 2355-2358 Pubmed, Volltext, DOI [7810]
Pettit NN. J Clin Pharm Ther. Feb 2016; 41(1): 101-3 Pubmed [7623]
Peyrière H. J Acquir Immune Defic Syndr. Mar 2004; 35(3): 269-73 Pubmed [7199]
Peyrin-Biroulet L. Aliment Pharmacol Ther. Oct 2008; 28(8): 984-93 Pubmed [6687]
Peyronneau MA. Eur J Biochem. Aug 1994; 223(3): 947-56 Pubmed [56]
Peytavin G. Eur J Clin Pharmacol. Jun 2005; 61(4): 267-73 Pubmed [7194]
Pezzoli G. Neurology. Mar 1995; 45(3 Suppl 3): S22-7 Pubmed [10965]
Pfeiffer E. J Agric Food Chem. Nov 2006; 54(23): 8769-74 Pubmed [12296]
Pfeiffer RF. Drug Saf. May 1996; 14(5): 343-54 Pubmed [12981]
Pfister M. Clin Pharmacol Ther. Aug 2002; 72(2): 133-41 Pubmed [6910]
Pfrepper C. Eur J Clin Pharmacol. Apr 2020; 76(4): 483-490 Pubmed [12461]
Pham HT. Expert Opin Pharmacother. Mar 2019; 20(4): 385-397 Pubmed [7635]
Pham Nguyen TP. Biomed Pharmacother. Jul 2021; 139: 111559 Pubmed [13609]
Pham PA. Antimicrob Agents Chemother. Oct 2009; 53(10): 4385-92 Pubmed, Volltext, DOI [4213]
Phan SV. Pharmacotherapy. Oct 2011; 31(10): 1017-30 Pubmed [12899]
pharmakologisch aus dem Wirkmechanismus und dem UAW-Profil der Kombinationspartner abgeleitet [610]
Pharmore GmbH. Fachinformation Deltaran. Stand Dec 2020. https://www.fachinfo.de/api/fachinfo/pdf/021207 [9684]
Phelan KM. J Clin Psychiatry. Nov 2003; 64(11): 1328-34 Pubmed [10074]
Phillips B. J Pharm Technol. Oct 2024; 40(5): 230-235 Pubmed [13832]
Phillips EJ. AIDS. Jul 2003; 17(10): 1577-8 Pubmed [6415]
Phillips EJ. Clin Pharmacol Ther. Apr 2018; 103(4): 574-581 Pubmed, Volltext, DOI [7851]
Phillips JP. J Clin Psychopharmacol. Oct 1986; 6(5): 297-9 Pubmed [6026]
Phiri K. PLoS One. Nov 2016; 11(11): e0165692 Pubmed, Volltext, DOI [8702]
Phua LC. Pharm Res. Nov 2008; 25(11): 2639-49 Pubmed [11778]
Piatkov I. World J Biol Psychiatry. Oct 2017; 18(7): 521-527 Pubmed [5128]
Picard N. Drug Metab Dispos. May 2005; 33(5): 689-95 Pubmed [327]
Picazo A. Life Sci. Nov 2006; 79(24): 2283-7 Pubmed [9713]
Pichard L. Mol Pharmacol. Jun 1992; 41(6): 1047-55 Pubmed [4494]
Picillo M. Parkinsonism Relat Disord. Dec 2009; 15 Suppl 4: S81-4 Pubmed [10975]
Pidlich J. Acta Med Austriaca. Jan 1997; 24(1): 15-8 Pubmed [4438]